Thrombocytopenia: Evaluation and Management.

Area of Science:

• Hematology
• Internal Medicine
• Pathophysiology

Background:

• Thrombocytopenia is defined as a platelet count below 150 × 10³ per μL.
• Severity correlates with bleeding risk: asymptomatic >50 × 10³ per μL, mild manifestations 20-50 × 10³ per μL, high risk <10 × 10³ per μL.
• While often linked to bleeding, conditions like antiphospholipid syndrome, heparin-induced thrombocytopenia, and thrombotic microangiopathies can present with both bleeding and thrombosis.

Purpose of the Study:

• To outline the diagnostic approach to thrombocytopenia.
• To differentiate between acute and chronic thrombocytopenia.
• To identify common causes and management strategies for thrombocytopenia.

Main Methods:

• Exclusion of pseudothrombocytopenia via repeat platelet counts in heparin or sodium citrate tubes.
• Distinguishing acute from chronic thrombocytopenia using historical platelet count data.
• Clinical evaluation to identify underlying causes such as immune, drug-induced, or HELLP syndrome.

Main Results:

• Isolated thrombocytopenia often indicates immune or drug-induced causes.
• Emergency hospitalization may be required for heparin-induced thrombocytopenia, thrombotic microangiopathies, and HELLP syndrome.
• Non-emergency causes include drug-induced, immune, and hepatic diseases.

Conclusions:

• Platelet transfusions are indicated for active hemorrhage or counts <10 × 10³ per μL, and before invasive procedures.
• Addressing the underlying cause is crucial for managing thrombocytopenia.
• Activity restrictions are advised for counts <50 × 10³ per μL to prevent trauma-related bleeding.